Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction
Top Cited Papers
- 20 February 2011
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (6) , 610-618
- https://doi.org/10.1200/jco.2010.30.5425
Abstract
Purpose: The prognosis of patients with colorectal cancer has sometimes proved uncertain; thus, the prognostic significance of immune criteria was compared with that of the tumor extension criteria using the American Joint Committee on Cancer/International Union Against Cancer–TNM (AJCC/UICC-TNM) staging system.Patients and Methods: We studied the intratumoral immune infiltrates in the center of the tumor and in the invasive margin of 599 specimens of stage I to IV colorectal cancers from two independent cohorts. We analyzed these findings in relation to the degree of tumor extension and to the frequency of recurrence.Results: Growth of the primary tumor and metastatic spread were associated with decreased intratumoral immune T-cell densities. Sixty percent of patients with high densities of CD8+cytotoxic T-lymphocyte infiltrate presented with stage Tis/T1 tumor, whereas no patients with low densities presented with such early-stage tumor. In patients who did not relapse, the density of CD8 infiltrates was inversely correlated with T stage. In contrast, in patients whose tumor recurred, the number of CD8 cells was low regardless of the T stage of the tumor. Univariate analysis showed that the immune score was significantly associated with differences in disease-free, disease-specific, and overall survival (hazard ratio [HR], 0.64, 0.60, and 0.70, respectively; P < .005). Time-dependent receiver operating characteristic curve analysis illustrated the predictive accuracy of the immune parameters (c-index = 65.3%, time-dependent c-index [Cτ] = 66.5%). A final stepwise model for Cox multivariate analysis supports the advantage of the immune score (HR, 0.64; P < .001; Cτ = 67.9%) compared with histopathologic features in predicting recurrence as well as survival.Conclusion: Assessment of CD8+cytotoxic T lymphocytes in combined tumor regions provides an indicator of tumor recurrence beyond that predicted by AJCC/UICC-TNM staging.This publication has 40 references indexed in Scilit:
- Data integration and exploration for the identification of molecular mechanisms in tumor-immune cells interactionBMC Genomics, 2010
- Microsatellite instability in colorectal cancer—the stable evidenceNature Reviews Clinical Oncology, 2010
- Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon CancerJournal of Clinical Oncology, 2009
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerNew England Journal of Medicine, 2008
- HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significanceOncogene, 2008
- Adoptive T cell therapy for cancer in the clinicJournal of Clinical Investigation, 2007
- Principles of adoptive T cell cancer therapyJournal of Clinical Investigation, 2007
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004
- Dangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic FactorsJNCI Journal of the National Cancer Institute, 1994